BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:02 PM
 | 
Jul 29, 2009
 |  BC Extra  |  Company News

Panel rebuffs Micardis for CV events in high risk patients

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 7-0 against approval of Micardis telmisartan from Boehringer Ingelheim GmbH (Ingelheim, Germany) to prevent cardiovascular events in...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >